Author:
González Soledad E.,Regairaz Lorena,R. Salazar Martín,Ferrando Noelia S.,González Martínez Verónica V.,Carrera Ramos Patricia M.,Pesci Santiago A.,Vidal Juan M.,Kreplak Nicolas,Estenssoro Elisa
Abstract
SummaryConvalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness remains controversial. Here we report the results of an Expanded Access Program of CPA in the province of Buenos Aires, Argentina. We evaluated the relationship between the timing of CPA and 28-day mortality in 4719 hospitalized patients with COVID-19 pneumonia. Early (≤3 days from admission) CPA was associated to decreased mortality in patients in the general ward and in the Intensive Care Unit not requiring mechanical ventilation. This suggests that the favorable effect of CPA might be related both to disease acuity and to the therapeutic window.
Publisher
Cold Spring Harbor Laboratory
Reference15 articles.
1. Kim MS , An MH , Kim WJ , Hwang TH . Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020. http:doi:10.1371/journal.pmed.1003501
2. RECOVERY Collaborative Group, et al. Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report. N Engl J Med. 2020. http:doi:10.1056/NEJMoa20214
3. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
4. Gobierno de la Provincia de Buenos Aires. Emergencia Sanitaria. Registro Único de Donantes de Plasma Convaleciente de la Provincia de Buenos Aires (RUDPCBA) para la obtención, procesamiento, distribución y recomendaciones terapéuticas sobre su uso en el tratamiento de pacientes con COVID-19. https://portal-coronavirus.gba.gob.ar/es/efectores-de-salud. Accessed January 21 2020
5. HHS Funds Development of Antibiotic to Treat Anthrax
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献